Lifecore Biomedical Provides Business Update
13 Décembre 2023 - 1:30PM
Lifecore Biomedical, Inc. (NASDAQ: LFCR) (the “Company”), a fully
integrated contract development and manufacturing organization
(“CDMO”), today provided a business update.
Lifecore is making significant progress towards
completing its Annual Report on Form 10-K for the fiscal year ended
May 28, 2023 (the “2023 Form 10-K”), which will include the
previously disclosed restatements for prior fiscal periods. The
Company expects to file the 2023 Form 10-K in the near term. The
Company’s work on its Quarterly Report on Form 10-Q for the fiscal
quarter ended August 27, 2023, is expected to commence immediately
following the completion of its 2023 Form 10-K and be filed upon
completion.
Lifecore continues to advance its development
portfolio with new and existing customers and is currently working
on the validation activities of its newly installed five-head
high-speed isolator filler. For the fiscal second quarter ended
November 26, 2023, the Company added one additional project for a
total of 32 projects in development and its development pipeline
continues to be active with multiple opportunities across
pre-clinical through late-phase of development as well as
commercial tech transfers.
Lifecore remains actively engaged in its
evaluation of potential strategic alternatives, which remains
ongoing. As previously announced, the Company has not set a
timetable for completion of this strategic review process, nor has
it made any decisions related to its strategic alternatives at this
time. There can be no assurance that this strategic review will
result in the Company pursuing a transaction or that any
transaction, if pursued, will be completed on attractive terms, or
at all.
About Lifecore Biomedical
Lifecore Biomedical, Inc. is a fully integrated contract
development and manufacturing organization (CDMO) that offers
highly differentiated capabilities in the development, fill and
finish of complex sterile injectable pharmaceutical products in
syringes and vials. As a leading manufacturer of premium,
injectable grade Hyaluronic Acid, Lifecore brings more than 40
years of expertise as a partner for global and emerging
biopharmaceutical and biotechnology companies across multiple
therapeutic categories to bring their innovations to market. For
more information about the Company, visit Lifecore’s website at
www.lifecore.com.
Important Cautions Regarding
Forward-Looking StatementsThis press release contains
forward-looking statements regarding future events and our future
results that are subject to the safe harbor created under the
Private Securities Litigation Reform Act of 1995 and other safe
harbors under the Securities Act of 1933 and the Securities
Exchange Act of 1934. Words such as “anticipate”, “estimate”,
“expect”, “project”, “plan”, “intend”, “believe”, “may”, “might”,
“will”, “should”, “can have”, “likely” and similar expressions are
used to identify forward-looking statements. All forward-looking
statements involve certain risks and uncertainties that could cause
actual results to differ materially, including such factors among
others, as the outcome of any evaluation of the Company’s strategic
alternatives or any discussions with any potential bidders related
thereto, the Company’s ability to become current with its reports
with the Securities and Exchange Commission (the “SEC”), and the
timing thereof, the Company’s ability to regain compliance with
applicable listing standards under Nasdaq. For additional
information about factors that could cause actual results to differ
materially from those described in the forward-looking statements,
please refer to our filings with the Securities and Exchange
Commission, including the risk factors contained in our most recent
Quarterly Report on Form 10-Q and Annual Report on Form 10-K/A.
Forward-looking statements represent management’s current
expectations and are inherently uncertain. Except as required by
law, we do not undertake any obligation to update forward-looking
statements made by us to reflect subsequent events or
circumstances.
Lifecore Biomedical, Inc. Contact
Information:Jeff Sonnek(646)
277-1263jeff.sonnek@icrinc.com
Lifecore Biomedical (NASDAQ:LFCR)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Lifecore Biomedical (NASDAQ:LFCR)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024